I would assume so given that they have acknowledged that this could be an issue in the past.
Agree it’s tough with 60 patients but it’s open label so maybe we’ll hear word of early successes given that LL is an early riser.
(2)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-